EDNRA and neoplasm: Early studies in various tumor cells revealed that spontaneous growth was significantly inhibited by ETAR antagonists, such as Atrasentan (ABT-627) and Zibotentan (ZD4054), demonstrating that endogenous ET-1 acts as an autocrine modulator of cell proliferation through ETAR [7,8,9].